$IPSC News

Century: 'Hold' Based On CNTY-101 Pivot And CNTY-813 T1D Curative Potential

Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific Sessions - Slideshow

Century Therapeutics Announces Presentation Of New Preclinical Data At American Diabetes Association Sessions Supporting CNTY-813 Novel Islet Cell Replacement Treatment

Mizuho Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $8

Century Therapeutics Q1 EPS $(0.11) Beats $(0.17) Estimate

H.C. Wainwright Remains Bullish on Century Therapeutics (IPSC)

Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions

Century Therapeutics To Highlight CNTY-813, iPSC-Derived Islet Cell Replacement Therapy Program Engineered With Allo-Evasion 5.0 For Patients With Type 1 Diabetes At ADA 86th Scientific Sessions

Century Therapeutics: A Biotech With Interesting Optionality Opportunities

HC Wainwright & Co. Maintains Buy on Century Therapeutics, Raises Price Target to $5

Century Therapeutics Maintains $150M ATM Program, With $131.6M Remaining In Capacity

iSpecimen Collects 500 Influenza Samples, Showcases Rapid Research Support

Century Therapeutics (NASDAQ:IPSC) Reports Narrower Loss, Extended Cash Runway to 2029

Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

Century Therapeutics Q4 EPS $(0.25) Beats $(0.27) Estimate

Century Therapeutics to Participate in Upcoming Investor Conferences in March

Reported Monday, iPSC-Derived NK Cells Clinical Trial Pipeline Gains Momentum With 12+ Active Companies Developing Off-The-Shelf Cancer Immunotherapy Treatments Across Multiple Indications

Reported Monday, iPSC-Derived NK Cells Clinical Trial Pipeline Gains Momentum With 12+ Active Companies Developing Off-The-Shelf Cancer Immunotherapy Treatments Across Multiple Indications

Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race

Century Therapeutics Files Prospectus For Offering 176.087M Common Shares